22:29:38Canada

AIM ImmunoTech Inc. (AIM)

NYSE American

Key stats Fiscal year 2025

Income statement

Revenue
88,000 -48.2%
Net income
-13,958,000
Operating income
-11,664,000
Earnings per share
-8.62
R&D expense
3,924,000

Growth and profitability

Operating margin
-13,254.55
Net margin
-15,861.36
Return on assets
-241.40

Balance sheet

Total assets
5,782,000
Total liabilities
15,565,000
Shareholders' equity
-9,783,000
Cash and equivalents
2,985,000
Debt
4,476,000
Net debt
1,491,000
Current ratio
0.53

Cash flow and ratios

Operating cash flow
-10,957,000

Shareholder returns

Shares outstanding
39,919,844
Revenue and net income
From revenue to profit 2025
Debt, free cash flow and cash
Earnings per share

Company information

Headquarters
Ocala, FL
Exchange
NYSE American
Fiscal year end
12-31
Industry (SEC)
Biological Products, (no Diagnostic Substances)

Fiscal year end: · Source: SEC EDGAR

AIM ImmunoTech Inc. trades on NYSE American under the ticker symbol AIM. This page brings together its price chart, company profile, key financial figures and technical indicators.

Company profile

Technical analysis